The currently approved therapies have encountered significant difficulties in the commercial market. Cell Therapies come with a high price tag, little long-term efficacy data, and expensive manufacturing processes. Now, the community must gather to:
- Achieve consistency in manufacturing, focusing on automation, allogeneic platforms, scalability, and engineering techniques
- Demonstrate durable response with enhanced construct design, optimized trial design, and long-term follow-up data
- Overcome solid tumor hurdles with combination strategy, specialized clinical delivery, and next-generation engineering strategies
These challenges require ground-breaking work, from discovery through to commercialization. Join us at the CAR-TCR Summit to learn from the key opinion leaders, and international innovators of the CAR-TCR community.